Prospective Multi-omics Observational Study of Gynecological Rare Pathological Tumors

Observational

Phase not listed

Sponsor: RenJi Hospital

Last Updated: August 14, 2023
Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.

The goal of this observational study is to draw the characteristic maps of genomics, transcriptome, proteomics, metabolomics, etc. in 600 patients with gynecological rare pathological types of malignant tumors. Then it is planned to explore the molecular mechanism and find some new targets for diagnosis and treatment, and design and establish the database system of the above rare tumors.

Treatment Category

Required Mutations

None

Trial Started

August 16, 2023

Last Updated by Sponsor

August 14, 2023

Estimated Completion

May 1, 2028

Contact Study

Eligibility

Inclusion Criteria

* 1)Pathological diagnosis: clear cell carcinoma (ovary, uterus), nerve small-cell carcinoma (ovary, uterus), carcinosarcoma or sarcoma (ovary, uterus), cervical gastric adenocarcinoma, ovarian germ cell tumor, ovarian sex cord stromal tumor, trophoblastic tumor, perivascular epithelioid cell tumor (PECOMA) and other rare gynecological tumors; 2)Received pathological results from tumor surgery; 3)The patient voluntarily participated in this research project with good compliance and was able to complete the enrollment according to the experimental requirements; 4)Sign the informed consent form and consent to the collection and use of their data, and consent to genomics, transcriptome and other tests.

Exclusion Criteria

* 1)Patients with malignant tumors in other parts of the body; 2)Suffering from uncontrollable neurological diseases, psychiatric diseases, or psychiatric disorders; 3)Poor compliance and inability to cooperate and describe treatment responders.

Do you think this trial is incorrectly appearing?

Design Details

AllocationN/A

Intervention ModelN/A

MaskingN/A

Number to Enroll600

Arms & Interventions

Arms

Interventions

No interventions available.

Outcome Measures

Primary Outcome Measures

Multi-omics feature mapAugust 2023 to May 2028

Draw the characteristic maps of imaging omics, genomics, transcriptome, proteomics, pathological omics, metabolomics, etc. of patients with gynecological rare pathological types of malignant tumors, and explore the molecular mechanism thus finding some new targets for diagnosis and treatment.

Database systemAugust 2023 to May 2028

Design and establish the database system of the above gynecological rare pathological types of tumors.

Secondary Outcome Measures

Correlation analysisAugust 2023 to May 2028

Integrate the characteristic maps of imaging omics, genomics, transcriptome, proteomics, pathological omics, metabonomics, etc. to study their possible relevance.